Simvastatin reduces the production of prothrombotic prostasomes in human prostate cancer cells

Summary

Cancer confers a prothrombotic state and statins are associated with a lowered risk for prostate cancer in vivo by unknown mechanisms. Prostate cancer cells release tissue factor (TF)-bearing, cholesterol-rich prostasomes which are procoagulant in vitro and a possible source for the blood-borne TF found in prostate cancer patients. We investigated the effect of cholesterol depletion on the production of prostasomes and on the TF activity in the conditioned medium of simvastatin-treated PC3 cells. Human PC3 prostate cancer cells were treated with high and low concentrations of simvastatin for different time periods. Caspase-3 was detected with the Array Scan microscope, where-asTF mRNA and protein were analyzed by TaqMan and flow cytometry. TF activity was assessed by measuring the cleavage of a chromogenic thrombin substrate. Prostasomes were isolated by repeated centrifugations and detected and quantified by flow cy tometry. A micromolar dose of simvastatin caused reduction of TF expression and induction of apoptosis in the PC3 cells. The levels of TF on the prostasomes were also decreased but the TF activity in the conditioned medium of the simvastatin-treated PC3 cells was increased due to apoptosis-dependent release of prostasomes. Treatment with a nanomolar dose of simvastatin did not induce apoptosis or alter the expression of TF but instead decreased the production and release of the prostasomes. The TF activity was reduced in parity with the decline in prostasome release. In conclusion, in prostate cancer, a nanomolar dose of simvastatin may have an anti-thrombotic effect due to decreased levels of circulating TF-bearing prostasomes.

Keywords

Apoptosis - deep vein thrombosis - malignancy - microparticles - tissue factor

• References

• 1 Prandoni P, Lensing AW, Buller HR. et al. Deepvein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1133.
• 2 Baron JA, Gridley G, Weiderpass E. et al. Venous thromboembolism and cancer. Lancet 1998; 351: 1077-1080.
• 3 Mann KG. Thrombin formation. Chest 2003; 124: 4S-10S.
• 4 Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003; 124: 58S-68S.
• 5 Mills PJ, Parker B, Jones V. et al. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. Clin Cancer Res 2004; 10: 4998-5003.
• 6 Wang J, Weiss I, Svoboda K. et al. Thrombogenic role of cells undergoing apoptosis. Br J Haematol 2001; 115: 382-391.
• 7 Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006; 118: 555-568.
• 8 Otten HM, Mathijssen J, ten CH. et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004; 164: 190-194.
• 9 Bogdanov VY, Balasubramanian V, Hathcock J. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 09: 458-462.
• 10 Giesen PL, Rauch U, Bohrmann B. et al. Bloodborne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-2315.
• 11 Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13: 269-288.
• 12 Hron G, Kollars M, Weber H. et al. Tissue factorpositive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 119-123.
• 13 Langer F, Chun FK, Amirkhosravi A. et al. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers. Thromb Haemost 2007; 97: 464-470.
• 14 Han LY, Landen Jr CN, Kamat AA. et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 2006; 24: 755-761.
• 15 Yu JL, Rak JW. Shedding of tissue factor (TF)-con-taining microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004; 02: 2065-2067.
• 16 Ronquist G, Nilsson BO. The Janus-faced nature of prostasomes: their pluripotency favours the normal reproductive process and malignant prostate growth. Prostate Cancer Prostatic Dis 2004; 07: 21-31.
• 17 Babiker AA, Ekdahl KN, Nilsson B. et al. Pro thrombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma. Semin Thromb Hemost 2007; 33: 80-86.
• 18 Fernandez JA, Heeb MJ, Radtke KP. et al. Potent blood coagulant activity of human semen due to prosta-some-bound tissue factor. Biol Reprod 1997; 56: 757-763.
• 19 Sahlen G, Ahlander A, Frost A. et al. Prostasomes are secreted from poorly differentiated cells of prostate cancer metastases. Prostate 2004; 61: 291-297.
• 20 Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
• 21 Platz EA, Leitzmann MF, Visvanathan K. et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819-1825.
• 22 Murtola TJ, Tammela TLJ, Lahtela J. et al. Cholesterol-lowering drugs and prostate cancer risk: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2226-2232.
• 23 Flick ED, Habel LA, Chan KA. et al. Statin Use and Risk of Prostate Cancer in the California Men’s Health Study Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2218-2225.
• 24 Jacobs EJ, Rodriguez C, Bain EB. et al. Cholesterol-Lowering Drugs and Advanced Prostate Cancer Incidence in a Large U.S. Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2213-2217.
• 25 Hoque A, Chen H, Xu Xc. Statin Induces Apoptosis and Cell Growth Arrest in Prostate Cancer Cells. Cancer Epidemiol Biomarkers Prev 2008; 17: 88-94.
• 26 Aberg M, Wickstrom M, Siegbahn A. Simvastatin induces apoptosis in human breast cancer cells in a NF[kappa]B-dependent manner and abolishes the antiapoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Thromb Res. 2008 in press.
• 27 Benitah SA, Valeron PF, van AL. et al. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 2004; 1705: 121-132.
• 28 Lovborg H, Nygren P, Larsson R. Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. Mol Cancer Ther 2004; 03: 521-526.
• 29 Malarstig A, Tenno T, Jossan S. et al. A quantitative real-time PCR method for tissue factor mRNA. Thromb Res 2003; 112: 175-183.
• 30 Llorente A, de Marco MC, Alonso MA. Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line. J Cell Sci 2004; 117: 5343-5351.
• 31 Carlsson L, Nilsson O, Larsson A. et al. Characteristics of human prostasomes isolated from three different sources. Prostate 2003; 54: 322-330.
• 32 Engstad CS, Lia K, Rekdal O. et al. A novel biological effect of platelet factor 4 (PF4): enhancement of LPS-induced tissue factor activity in monocytes. J Leukoc Biol 1995; 58: 575-581.
• 33 Engstad CS, Gutteberg TJ, Osterud B. Modulation of blood cell activation by four commonly used anticoagulants. Thromb Haemost 1997; 77: 690-696.
• 34 Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
• 35 Sahlen GE, Egevad L, Ahlander A. et al. Ultrastructure of the secretion of prostasomes from benign and malignant epithelial cells in the prostate. Prostate 2002; 53: 192-199.
• 36 Rang HP, Dale MM, Ritter JM. Pharmacology. 4th ed. Churchill Livingstone; 1999: 305-306.
• 37 Arvidson G, Ronquist G, Wikander G. et al. Human prostasome membranes exhibit very high cholesterol/ phospholipid ratios yielding high molecular ordering. Biochim Biophys Acta 1989; 984: 167-173.
• 38 Babiker AA, Hamad OA, Sanchez J. et al. Prothrombotic effect of prostasomes of metastatic cell and seminal origin. Prostate 2007; 67: 378-388.
• 39 Eiseman G, Stefanini M. Thromboplastic activity of leukemic white cells. Proc Soc Exp Biol Med 1954; 86: 763-765.
• 40 Hamada K, Kuratsu J, Saitoh Y. et al. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996; 77: 1877-1883.
• 41 Kakkar AK, Lemoine NR, Scully MF. et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82: 1101-1104.
• 42 Shigemori C, Wada H, Matsumoto K. et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998; 80: 894-898.
• 43 Ueno T, Toi M, Koike M. et al. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83: 164-170.
• 44 Versteeg HH, Spek CA, Peppelenbosch MP. et al. Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med 2004; 10: 6-11.
• 45 Abe K, Shoji M, Chen J. et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999; 96: 8663-8668.
• 46 Shoji M, Hancock WW, Abe K. et al. Activation of coagulation and angiogenesis in cancer: immunohisto-chemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152: 399-411.
• 47 Bromberg ME, Konigsberg WH, Madison JF. et al. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92: 8205-8209.
• 48 Siegbahn A, Johnell M, Rorsman C. et al. Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis. Blood 2000; 96: 3452-3458.
• 49 Jiang X, Guo YL, Bromberg ME. Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost 2006; 96: 196-201.
• 50 Lechner D, Kollars M, Gleiss A. et al. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost 2007; 05: 2445-2452.